Sold before it exists: the company is already taking committed orders or reservations for output it cannot yet produce
The model's full reasoning — Q3 2018 call → NOWe need to determine if the transcript shows that counterparties have already committed to take output, product, capacity, or service that the company is not yet able to deliver. The question asks for a specific situation where commitments are real and already made, and the ability to supply does not yet fully exist, with the gap being closed now. Let's review the transcript. The company discusses various products: VIVITROL, ARISTADA, ALKS 5461, ALKS 3831, BIIB098, ALKS 4230. They talk about launches, clinical trials, regulatory decisions, etc. Key points: - For ARISTADA INITIO, they mention launch, formulary additions, and expansion of sales force. But that's about existing product and marketing. - For ALKS 5461, they are awaiting FDA decision and AdCom. No commitments from buyers. - For ALKS 3831, they are awaiting data. - For BIIB098, they are submitting NDA, but that's with Biogen collaboration. No mention of commitments from buyers. - For ALKS 4230, they are in clinical trials. The question is about counterparties committing to take output, product, capacity, or service that the company is not yet able to deliver. This sounds like pre-sales, offtake agreements, or similar. In the transcript, there is no mention of any such commitments. They talk about sales force expansion, but that's for existing products. They talk about potential launches, but no commitments from customers. The only possible thing is maybe the collaboration with Biogen for BIIB098, but that's a development collaboration, not a commitment to take output. Also, they mention that they are preparing for launch of 5461, but no commitments. Thus, the answer is NO. The company is not describing any counterparties that have already committed to take future output that they cannot yet deliver. They are building capabilities in anticipation of demand, but no commitments are mentioned. So answer NO.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| SYM | Symbotic Inc. | Q3 2022 | 2022-08-01 | B+ |
| BXP | Boston Properties, Inc. | Q1 2022 | 2022-05-03 | A |
| CPK | Chesapeake Utilities Corporation | Q3 2017 | 2017-11-10 | A |
| GOGO | Gogo Inc. | Q1 2016 | 2016-05-06 | C+ |
GOGO · Q1 2016 → YESThe question is: Does management describe that counterparties have already committed to take output, product, capacity, or service that the company is not yet able to deliver? YES Management describes real commitments (Delta >600, IAG 130+, Shareco 50, Air Canada wide-body fleet, total 2Ku awarded >1000) already made by counterparties. They also state the company is not yet able to deliver at scale ("begin the enviable task of installing the 1000 2Ku awarded aircraft", "we expect to install the majority of our awarded aircraft by the end of 2018", "STCs... will keep us on track to exceed our 75 2Ku installation target this year", "supply chain is there", "aggressive STC program...
SYM · Q3 2022 → YESThe question is: Does management describe that counterparties have already committed to take output that the company is not yet able to deliver? Like a backlog of things they haven't built yet. YES The transcript shows management describing a $11.3 billion contracted revenue backlog (more than doubled) with customers having "voted with their wallets," alongside 13 systems currently in deployment (plus 6 fully ramped) that will take roughly 18 months to acceptance.
BXP · Q1 2022 → YESThe question is about whether management describes counterparties that have already committed to take output that the company is not yet able to deliver, like pre-leased developments that aren't built...YES The transcript shows multiple instances where management describes counterparties having already signed leases for space in developments that have not yet been completed or even commenced construction.